Clinical Trial Update: Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of GS-9256 and GS-9190, alone and with ribavirin, over 28 days in chronic hepatitis C patients, has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GS-9190
• GS-9256
• Ribavirin (ribavirin)

Snippet

Sponsor: Gilead Sciences | Conditions: HCV Infection | Phase 2 | Status: COMPLETED